Title:
USE OF IMMUNOCYTOKINE COMPRISING INTERFERON-BETA OR VARIANT THEREOF FOR TREATING HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE CANCER
Document Type and Number:
WIPO Patent Application WO/2021/034098
Kind Code:
A1
Abstract:
The present invention relates to a use of a recombinant protein in which interferon-beta and an antibody binding to a HER2 antigen are fused for the purpose of treating cancer patients of which the HER2 expression level is IHC 1+ or higher. The recombinant protein can exhibit efficacy better than conventional antibody therapeutic agents through cancer-specific anti-cancer immune responses in patients, thereby being used for more patients, and thus is effectively usable as a novel agent for treating cancer.
Inventors:
JEONG HAE MIN (KR)
LEE JI SUN (KR)
LEE JI SUN (KR)
Application Number:
PCT/KR2020/011030
Publication Date:
February 25, 2021
Filing Date:
August 19, 2020
Export Citation:
Assignee:
GENOPHARM INC (KR)
International Classes:
A61K47/68; A61K38/21; A61K39/00; A61P35/00; C07K14/565; C07K16/32
Domestic Patent References:
| WO2018160538A1 | 2018-09-07 |
Foreign References:
| KR20160107070A | 2016-09-13 | |||
| KR100781666B1 | 2007-12-03 | |||
| KR20100084634A | 2010-07-27 | |||
| KR20190101351A | 2019-08-30 |
Other References:
YOUNG PATRICIA A; MORRISON SHERIE L; TIMMERMAN JOHN M: "Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.", SEMINARS IN ONCOLOGY, ELSEVIER, US, vol. 41, no. 5, 30 September 2014 (2014-09-30), US, pages 623 - 636, XP009506872, ISSN: 1532-8708, DOI: 10.1053/j.seminoncol.2014.08.002
CHOUTALALAY, ADV. ENZYME. REGUL., vol. 22, 1984, pages 27 - 55
CHOUTALALAY, ADV. ENZYME. REGUL., vol. 22, 1984, pages 27 - 55
Attorney, Agent or Firm:
LEE, Hee Sook (KR)
Download PDF: